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To the Editor: We reported the short-term results (6-month
ollow-up) of a pilot study of the role of stem cell therapy in
schemic cardiomyopathy (1). We now present the final long-term
3-year follow-up) results of the trial. The study included patients
etween 15 and 70 years of age with idiopathic dilated cardiomy-
pathy with normal coronary arteries, an ejection fraction (EF) of
40%, and no other severe comorbidities (e.g., chronic renal
ailure). The study design was an open-label, randomized trial in
hich 85 patients were enrolled. The end points of the study were
) change in New York Heart Association (NYHA) functional
lass, 2) change in quality of life per the Kansas City Cardiomy-
pathy Questionnaire (KCCQ), 3) change in left ventricular
unction (Vivid 7TM,Wipro GEHealthcare, offline analysis using
impson’s method), and 4) mortality. An endomyocardial biopsy
as performed in 8 patients. After administering local anesthesia,
one marrow (60 ml) was aspirated from the iliac crest using a
terile bone marrow aspiration needle, and mononuclear bone
arrow stem cells were separated using the Ficoll density separa-
ion method. A mean volume of 59  2 ml of bone marrow was
emoved. This contained 168  96 million cells, of which
.71.5 million cells were CD34 cells and showed 92% viability.
uring stem cell injection, the coronary sinus ostium was
annulated with a 6-F Swan-Ganz catheter (Arrow Interna-
ional, Reading, Pennsylvania) with a reverse loop within the
ight atrium. The balloon was inflated, ensuring that the distal
ressure did not increase to more than the diastolic pressure
this slowed the flow of blood from the coronary sinus, possibly
llowing a longer time for cell migration and homing). Subse-
uently, the left coronary was hooked, and two-thirds of the
tem cell concentrate was injected slowly. The entire procedure
as repeated for the right coronary artery. Clinical and echo-
ardiographic follow-up was performed.
Eighty-five patients with similar demographics, left ventricular
olumes and function, and functional status score (KCCQ) were
tudied in 2 groups (treatment arm and control arm). The mean
ollow-up period was 28  9 months. Two patients in the treatment
rm were lost to follow-up, and another 2 patients underwent
iventricular pacing. Among the remaining 41 patients, 10 (24.4%)
atients died within 3 years. There were 12 NYHA functional class
V patients, and of them, 6 died during the follow-up period and 5
atients showed improvement (1 patient to class I, 1 patient to class
II, and the remaining 3 patients to class II). Mortality was not
ignificantly different between the treatment and control arms. The
F improved in the treatment arm by 5.9% with a reduction in
nd-systolic volumes and no change in end-diastolic volumes. Both
YHA functional class III and IV groups in the treatment arm
howed improvement, although the effect on the NYHA functional
lass III patients (EF: 23.6 10.6.% to 30.1 11%) was greater than ohat on the NYHA functional class IV patients (EF: 20.1 9% to 24
13.8%). There was no significant improvement in the EF in the
ontrol patients (Table 1). There was a significant improvement in
uality of life as assessed by KCCQ and functional status on
ong-term follow-up in the treatment group (Table 1). Endomyocar-
ial biopsies showed a trend toward improvement in vascularity with
o definite evidence of transdifferentiation (1). This was in the form
f significantly increased capillary density with no increase in the
upporting pericytes. No new myocardial cells or any immature cells
ere seen.
Recently, the results of a few small trials were reported that
uggest a beneficial role of stem cell therapy in nonischemic
ilated cardiomyopathy (2–4). Kalil et al. (2) showed intramyo-
ardial transplantation of bone marrow stem cells in dilated
ardiomyopathy patients with improvement in functional class
ithout improvement in left ventricular function. Wang et al.
3) also found similar results after intracoronary infusion of
utologous mesenchymal stem cells. Kaparthi et al. (4) showed
mprovement in functional status and left ventricular function
fter intracoronary autologous bone marrow mononuclear cells
nfusion. Large randomized trials are ongoing in Brazil, Eu-
ope, and India.
In the initial 6 months of the ABCD (Autologous Bone
arrow Cells in Dilated Cardiomyopathy) trial (1), we found
hat 76% of our patients who were NYHA functional class III
howed an improvement in EF by 5.4%. This improvement
anifested after 1 month, which is too early to be explained by
ormation of fresh myocytes. This benefit was predominantly
ue to improvement in end-systolic volumes while the end-
iastolic volumes remained the same. This is similar to a
umber of other studies that also showed an improvement in
F of about 4% to 6%, and also with no change in end-diastolic
olumes. This would suggest that stem cells do not cause any
hange in the remodeling process but improve myocardial cell
unction. In animal models of dilated cardiomyopathy, direct
njection of mesenchymal stem cells has been shown to signif-
cantly increase capillary density and decrease the collagen
olume fraction in the myocardium, resulting in decreased left
entricular end-diastolic pressure and increased left ventricular
ystolic function. This is similar to our histopathological data
howing a trend toward increasing vascularity (1).
In summary, the clinical follow-up results of a first-in-man pilot
tudy of stem cell therapy in patients with dilated cardiomyopathy
t the completion of 3 years of follow-up demonstrate that the
enefit is sustained and without any long-term side effects. is the
ffect is less in patients with more severely damaged myocardium.
his study establishes the long-term safety and long-term efficacy
f this therapy in dilated cardiomyopathy.
**
C
A
N
I
E
B
R
R
S
G
L
B
P
f
P
B
M
K
V
I
E
I
R
1
2
3
4
S
C
(
l

E
V
D
3
ity Card
1644 Correspondence JACC Vol. 55, No. 15, 2010
April 13, 2010:1643–7Sandeep Seth, MD, DM
Department of Cardiology
ardiothoracic Sciences Center
ll India Institute of Medical Sciences
ew Delhi 110029
ndia
-mail: drsandeepseth@hotmail.com
alram Bhargava, MD, DM
ajiv Narang, MD, DM
uma Ray, MD, MRC Path
ujata Mohanty, PhD
urpreet Gulati, MD
alit Kumar, MD, DM
alram Airan, MS, MCh
anangipalli Venugopal, MS, MCh
or the AIIMS Stem Cell Study Group
doi:10.1016/j.jacc.2009.11.070
valuation at Follow-Up of Cell TherapyTable 1 Eva uation at Fo ow-Up of Cell Therapy
T
Baseli
Clinical data
Age, yrs 45
Sex, male 33
NYHA functional class for dyspnea
I 0
II 0
III 29 (7
IV 12 (2
Mortality
KCCQ
Functional status score 51.19
Clinical summary score 59.81
Echocardiography data
End-systolic volume, ml 137.3
End-diastolic volume, ml 176.7
Ejection fraction, % 22.5
Treatment at 3 yrs
ACE inhibitor or ARB (ramipril equivalent), % taking drug
Dose, mg
Beta-blocker (carvedilol equivalent), % taking drug
Dose, mg
alues are mean  SD or n (%) of patients. Continuous variables were compared using a Wilcoxo
ifferences in mortality were compared by the Fisher exact test. All analyses were performed with
years for treatment group. †p  0.05 between treatment arm and control arm.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; KCCQ  Kansas Clease note: The AIIMS Stem Cell Study Group: Sandeep Seth, MD, DM, Balram
hargava, MD, DM, Rajiv Narang, MD, DM, Ruma Ray, MD, MRC Path, Sujata
103 pmol/l [868 pg/ml]), had a greater clinical benefit from
r
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0
cohanty, PHD, Gurpreet Gulati, MD, Sanjeev Sharma, Lalit Kumar, MD, DM,
apil Kumawat, Neeraj Parakh, Praloy Chakroborty, Balram Airan, Panangipalli
enugopal, MS, MCh. This work was done with the Research Funds of the All India
nstitute of Medical Sciences under the Stem Cell Research Program at the Centre of
xcellence for Stem Cell Research, Department of Biotechnology, Government of
ndia.
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12 (24.4) 14 (30)
67.02 21.8* 51.52 18.12 52.74 18.8†
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41 (100) 40 (100)
7.5 1.2 7.4 1.7
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12.5 5 12.1 3
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trial. Afr J Biotechnol 2008; 7:207–10.Letters to the Editortatins and Heart Failure
leland et al. (1) report that patients with less severe heart failure
HF) due to ischemic heart disease (IHD), as indicated by lower
evels of N-terminal pro–B-type natriuretic peptide (lower tertile,osuvastatin (hazard ratio [HR]: 0.65; 95% confidence interval
CI]: 0.47 to 0.88, p  0.005), despite the lower absolute event
ate, contrary to the results of the original study (2).
We reported that treatment with atorvastatin (mean dose 23
g/day) of 800 IHD patients resulted in a reduction of 50% (HR:
.50; 95% CI: 0.27 to 0.94, p  0.021) in new cases or worseningreatm
ne
15
1)
9)
19.90
20.27
62.6
76.40
8.3
n 2-sam
SPSS fases of HF requiring hospitalization versus 800 IHD patients
